Johnson & Johnson reported $33.8 billion in MedTech sales for 2025, a 6.1% increase from the prior year.
Operational sales for the segment grew 5.4%, driven by cardiovascular and surgical products, according to a Jan. 21 earnings release. The company also highlighted regulatory progress on its robotic surgical system, which was submitted for review in 2025. The platform is part of J&J’s broader strategy to expand its footprint in minimally invasive and digitally integrated surgery.
J&J projects reported sales of up to $101 billion in 2026, with MedTech performance expected to remain a key driver.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.